Mercury II - compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin with Rosuvastatin in High Risk Subjects with type IIa and IIb Hypercholesterolemia
Study identifier:4522IL/0068
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group Switching Study to compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin with Rosuvastatin in High Risk Subjects with type IIa and IIb Hypercholesterolemia.
Medical condition
Hypercholesterolemia
Phase
Phase 3
Healthy volunteers
No
Study drug
Rosuvastatin, Atorvastatin, Simvastatin
Sex
All
Actual Enrollment
4875
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Nov 2001
Primary Completion Date: -
Study Completion Date: 01 Sept 2004
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Rosuvastatin | - |
| Active Comparator: 2 Atorvastatin | - |
| Active Comparator: 3 Simvastatin | - |
Contacts
Investigators
Principal Investigator
Joel Raichlen
AstraZeneca
